FDA approves belzutifan plus lenvatinib for advanced clear cell RCC

FDA approval · FDA · 2026-09-24. Number 4 in the UrologyWatch Top 5 for September 26, 2026.

The FDA approved the combination of belzutifan and lenvatinib for advanced renal cell carcinoma with a clear cell component.

Why it matters: Adds a new combination option for patients with advanced clear cell RCC.

Source: FDA

The full September 26, 2026 edition · Today's urology news